Biotest AG

Biotest prepares launch of its immunoglobulin Yimmugo in the USA, establishing a framework for a strategic billion-dollar distribution agreement with Kedrion

Biotest’s sustainability campaign GoFuture part of the new documentary ‘Future Seeds’

Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo

Biotest AG: Annual General Meeting approves dividend distribution

Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

Biotest AG opens 12th plasma collection centre in Germany

Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 07.05.2024 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Biotest AG increased sales by 32% in the financial year 2023

Biotest achieves EBIT forecast for 2023

Karl Lauterbach visits Biotest AG’s plasma donation centre in Cologne and emphasises important contribution to patient care

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate

Biotest AG opens 11th plasma collection centre in Germany

Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)

Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation

Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Biotest AG: Increase of the EBIT guidance

Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG

Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK

Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin

Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin Yimmugo

Biotest AG: Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study

Biotest AG: Biotest Supervisory Board extends Management Board contract of Dr Jörg Schüttrumpf by 5 years

Biotest AG: Biotest increases EBIT to Euro 19.8 million in the first half of 2023

Biotest AG: Biotest increases EBIT to Euro 19.8 million

Biotest AG: Biotest presents gigantic artwork to visualize its sustainability initiatives

Biotest AG: Annual General Meeting of Biotest AG elects Raimon Grifols Roura to the Supervisory Board

Biotest AG: Biotest’s Hyperimmunoglobulin Cytotect® CP receives five additional Marketing Authorisations in Europe